Cancer patients have often been excluded from studies of cardiovascular disease (CVD) and patients with significant CVD have been excluded from studies of new cancer therapies. Consequently, the ability to determine the incidence or prevalence of cardiovascular toxic effects of anticancer agents and their optimal management has been limited. This multidisciplinary module presents a case study of a patient with a history of coronary artery disease who is diagnosed with renal cell carcinoma and treated with a tyrosine kinase inhibitor.
- Enhance awareness of the different types of tyrosine kinase inhibitor (TKI)-associated cardiotoxicities, specifically for sunitinib in the treatment of renal cell carcinoma.
- Describe the various mechanisms of cardiotoxicity from TKIs.
- Identify and assess patients at high-risk for cardiotoxicity from TKIs.
- Apply treatment management strategies for patients experiencing cardiotoxic effects from TKI anti-cancer treatment.
- Discuss the treatment approaches for other TKIs.
CME Credit is available for this course.
ACGME Competency Addressed: Medical Knowledge